调节TREM2重塑瘤骨髓形状,增强抗PD-1免疫疗法
Martina Molgora1, Ekaterina Esaulova1, William Vermi2
1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Cell
|August 14, 2020
概括
向TREM2 (在骨髓细胞2表达的触发受体) 可以增强癌症免疫疗法. 在小鼠中阻断TREM2通过改变骨髓细胞群减少了瘤生长,并改善了对抗PD-1治疗的反应.
科学领域:
- 免疫学
- 癌症学
- 神经科学
背景情况:
- 检查点免疫疗法是一种有前途的癌症治疗方法,但其有效性往往受到瘤微环境中的免疫抑制性骨髓细胞的限制.
- TREM2 (在骨髓细胞2上表达的触发受体) 是一个对大脑微质功能至关重要的骨髓受体,也存在于瘤透的巨细胞上.
- 了解TREM2在癌症中的作用对于开发新疗法至关重要.
研究的目的:
- 研究TREM2在瘤生长中的作用及其对抗PD-1免疫治疗反应的影响.
- 确定TREM2的向是否可以克服癌症中髓质介导的免疫抑制.
- 探索TREM2作为增强癌症免疫疗法的治疗点的潜力.
主要方法:
- 使用Trem2淘汰赛 (Trem2-/-) 小鼠来评估瘤耐药性和免疫治疗反应.
- 与抗PD-1疗法联合使用的抗TREM2单克隆抗体 (mAb).
- 使用单细胞RNA测序 (scRNA-seq) 来分析瘤透的骨髓细胞群.
- 在人类癌症组织中检查TREM2表达.
主要成果:
- 与野生型小鼠相比,Trem2-/-小鼠对各种癌症的耐药性增加,对抗PD-1免疫疗法的反应提高.
- 使用抗TREM2 mAb和抗PD-1的联合治疗显著抑制了瘤的生长,并促进了瘤的回归.
- scRNA- seq显示TREM2的删除或阻断导致免疫抑制MRC1+和CX3CR1+巨细胞的减少.
- 这伴随着免疫刺激性髓质子集的扩大,促进了T细胞反应的改善.
- 在200多例人类癌症中,瘤巨细胞的TREM2表达与两种癌症患者的存活率相反相关.
结论:
- 通过支持免疫抑制性骨髓细胞群,TREM2在促进瘤生长和免疫逃避方面发挥着关键作用.
- 针对TREM2,无论是基因还是药物, 可以重新编程瘤骨髓透.
- 阻断TREM2与抗PD-1等检查点抑制剂相结合,是增强抗瘤免疫力和改善患者癌症治疗结果的有希望的策略.
相关概念视频
Tumor Immunotherapy
1.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
The Tumor Microenvironment
7.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.5K
Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K
Tumor Progression
7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K


